Krystal Biotech (NASDAQ:KRYS) CAO Sells $3,401,750.00 in Stock

Krystal Biotech, Inc. (NASDAQ:KRYS) CAO Kathryn Romano sold 12,500 shares of the stock in a transaction dated Monday, February 9th. The shares were sold at an average price of $272.14, for a total transaction of $3,401,750.00. Following the completion of the transaction, the chief accounting officer directly owned 19,318 shares in the company, valued at approximately $5,257,200.52. This represents a 39.29% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Krystal Biotech Trading Up 0.7%

Shares of NASDAQ:KRYS traded up $1.95 during trading on Wednesday, reaching $272.65. 179,084 shares of the stock were exchanged, compared to its average volume of 259,033. Krystal Biotech, Inc. has a 12 month low of $122.80 and a 12 month high of $295.98. The firm has a market cap of $7.91 billion, a PE ratio of 40.58 and a beta of 0.49. The stock has a 50-day moving average price of $260.24 and a 200-day moving average price of $204.03.

Analyst Ratings Changes

A number of brokerages have commented on KRYS. Zacks Research lowered Krystal Biotech from a “strong-buy” rating to a “hold” rating in a report on Thursday, February 5th. Guggenheim set a $224.00 target price on shares of Krystal Biotech and gave the company a “buy” rating in a research report on Friday, October 17th. Bank of America raised their price target on shares of Krystal Biotech from $288.00 to $318.00 and gave the stock a “buy” rating in a research report on Thursday, January 22nd. Weiss Ratings reiterated a “hold (c+)” rating on shares of Krystal Biotech in a research note on Monday, December 29th. Finally, Chardan Capital increased their target price on shares of Krystal Biotech from $216.00 to $220.00 and gave the stock a “buy” rating in a research report on Tuesday, November 4th. Nine equities research analysts have rated the stock with a Buy rating and two have issued a Hold rating to the company’s stock. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $277.89.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently bought and sold shares of KRYS. Royal Bank of Canada boosted its stake in Krystal Biotech by 145.2% in the first quarter. Royal Bank of Canada now owns 1,628 shares of the company’s stock valued at $294,000 after buying an additional 964 shares in the last quarter. AQR Capital Management LLC boosted its stake in shares of Krystal Biotech by 29.9% in the 1st quarter. AQR Capital Management LLC now owns 12,131 shares of the company’s stock valued at $2,187,000 after purchasing an additional 2,792 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its holdings in shares of Krystal Biotech by 4.5% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 15,893 shares of the company’s stock valued at $2,870,000 after purchasing an additional 688 shares during the last quarter. Empowered Funds LLC bought a new stake in shares of Krystal Biotech during the 1st quarter valued at approximately $218,000. Finally, Vontobel Holding Ltd. increased its position in Krystal Biotech by 13.9% during the 2nd quarter. Vontobel Holding Ltd. now owns 3,075 shares of the company’s stock worth $423,000 after purchasing an additional 375 shares in the last quarter. Institutional investors and hedge funds own 86.29% of the company’s stock.

About Krystal Biotech

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.